Three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, have been approved for use in the US for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in combination with endocrine therapy [37]. This evidence concerns the gene CDK4 and breast carcinoma.